Published in Biotech Business Week, April 11th, 2005
The company's clinical program for AMD070 is being conducted by leading investigators at the U.S. Adult AIDS Clinical Trials Group (ACTG), which is supported by the National Institute of Allergy and Infectious Diseases at the National Institute of Health.
"This clinical study in HIV patients will determine if AMD070 has the potential to become a new and important anti-HIV drug. AMD070, a member of a new class of HIV drugs called entry inhibitors, prevents the virus from infecting...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.